ArticleThe Journal of clinical endocrinology and metabolism2025
Telemedicine Visit Use and Glycemic Control in Patients With Diabetes.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
contextEndocrinology telemedicine visits increased during the COVID-19 pandemic with unclear impacts on patient outcomes.
objectiveTo determine the relationship between different rates and types of telemedicine use and glycemic control in patients with diabetes.
methodsThis was a retrospective cohort study conducted in endocrinology clinics at an integrated health system. Patients were adults with a baseline glycated hemoglobin (HbA1c) measurement in 2020, at least 2 diabetes visits in 2021, and an outcome HbA1c assessment in 2022. The proportion of total visits in 2021 conducted by video or phone was analyzed and the primary outcome was the change in HbA1c between baseline and the 2022 assessment.
resultsThe study population (n = 8867) was 51.39% female, with a mean age of 63.90 years and baseline HbA1c of 7.72%. Patients had a mean of 35.09% telemedicine visits in 2021 (25.18% video, 9.91% phone). Between 2020 and 2022, HbA1c decreased by a mean of 0.17%. Multivariable regression analysis adjusted for demographic and clinical covariates demonstrated that higher rates of phone (P = .009) but not video visits were associated with a smaller decrease in HbA1c. When stratified by baseline HbA1c, higher rates of phone visits were associated with a smaller decrease in HbA1c in patients with a baseline HbA1c ≥ 8.0% (P = .001) but not in those with a baseline HbA1c < 8.0%.
conclusionHigher rates of phone but not video visits were associated with worse glycemic control in patients with higher baseline HbA1c. Additional research is needed to determine possible causes and strategies for bridging the digital divide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.